INTRODUCTION {#S1}
============

The random rearrangement of T cell receptor (TCR) genes generates T cells with a broad range of specificities, including T cells specific for self-antigens. To circumvent this, self-specific T cells escaping central tolerance acclimate to self-antigen and become non-responsive ([@R30]; [@R47]). While tolerance is ideal for controlling autoimmunity, it is a barrier for tumor immunotherapy, as many of the same tolerance mechanisms restrain tumor-specific T cells ([@R45]).

Tumor neo-antigens are important targets for immunotherapies ([@R21]; [@R46]). However, targeting neo-antigens is complex, as they are unique and unevenly expressed. Self-antigens can be uniformly overexpressed in tumors. Self-specific CD8 T cells also have the potential to patrol for cancer recurrence, whereas neo-antigen-specific T cells could lose this ability, as relapses may not harbor the same neo-antigens ([@R29]). Thus, many groups have attempted to generate populations of self-specific T cells as immunotherapies ([@R25]; [@R35], [@R36]; [@R59]). However, such manipulation may precipitate autoimmunity. Thus, there is an opportunity for the development of *in vivo* modalities that activate tolerant T cells in a targeted fashion to generate large numbers of self-specific T cells for immunotherapy, yet induce no or self-resolving autoimmune pathology.

Tissue resident memory T cells (T~RM~) play a significant role in anti-tumor immunity ([@R12]; [@R25]; [@R33]). Recently, it has been shown that both circulating and T~RM~ cells have anti-tumor potential and may synergize to prevent tumor outgrowth ([@R12]). Thus, simultaneously enhancing both T cell populations is key for optimal anti-tumor responsiveness ([@R5]; [@R33]).

We set out to probe the plasticity of self-specific CD8 T cells under the control of central and/or peripheral tolerance. Through robust systemic and iterative stimulation with vectors containing self-antigens, functional self-specific CD8 T cells can be generated from the previously non-responsive CD8 T cell repertoire. This is true for endogenous self-specific CD8 T cells and high-affinity transgenic self-specific CD8 T cells. Cumulative antigenic stimulation drives avidity maturation of tolerant CD8 T cells and contributes to increased antigen sensing. Expanded self-specific CD8 T cells are dispersed throughout the body and become T~RM~ in lymphoid and non-lymphoid organs. The amplification of these self-specific T cells delays the growth of tumors bearing self-antigens without autoimmunity. Immunotherapy using neo-antigen-specific CD8 T cells is augmented by self-specific CD8 T cell responses. These studies reveal that antigen-induced T cell non-responsiveness can be reversed with proper antigenic exposure and opens the possibility of co-opting self-specific T cell responses for the treatment of cancer.

RESULTS {#S2}
=======

Reversal of Established Peripheral Tolerance in High-Affinity Self-Specific CD8 T Cells {#S3}
---------------------------------------------------------------------------------------

We used intestinal fatty acid-binding protein (iFABP)-Ova mice, in which ovalbumin (Ova) is a self-protein in the small intestine, to generate a known population of anergic CD8 T cells ([@R37]; [@R56]). When naive OTI (high-affinity transgenic CD8 T cells specific for Ova) are transferred to adult iFABP-Ova mice, OTI cells quickly become tolerized in the absence of infection, antigen-presenting cell (APC) maturation signals, or checkpoint blockade ([@R32]; [@R37]; [@R55]; [@R56]). After 30 days in iFABP-Ova hosts, OTI cells are PD-1^+^, do not produce cytokines, and are refractory to PD-L1, PD-1, CTLA4, LAG-3, and/or TIM-3 blockade ([@R32]; [@R37]). These data mirror the dysfunction of tumor-specific CD8 T cells, which is thought to be fixed by day 14 after initial antigen encounter ([@R38]; [@R44]., [@R45]). Dysfunctional self-specific OTI cells are maintained long term (at least 359 days) in iFABP-Ova mice ([Figures 1A](#F1){ref-type="fig"}, [1B](#F1){ref-type="fig"}, and [S1](#SD1){ref-type="supplementary-material"}).

To assess whether non-responsiveness could be reversed for high-affinity OTI cells, iFABP-Ova mice with tolerant OTI cells were infected with vesicular stomatitis virus (VSV)-Ova. This induced OTI expansion in the blood and non-lymphoid tissues (NLTs), despite our previous data that tolerant OTI cells do not proliferate or produce cytokines after checkpoint blockade alone ([Figures 1B](#F1){ref-type="fig"}, [1C](#F1){ref-type="fig"}, and [S1](#SD1){ref-type="supplementary-material"}) ([@R32]; [@R37]). A 53-fold expansion in peripheral blood leukocytes (PBLs) occurred by day 7 after VSV-Ova and these cells are maintained long term ([Figures 1C](#F1){ref-type="fig"} and [S1](#SD1){ref-type="supplementary-material"}). Thus, tolerance can be reversed *in vivo* for high-affinity self-specific CD8 T cell populations that appear to be in a fixed dysfunctional state and are resistant to checkpoint blockade.

Tolerance reversal has been shown to be transient, and self-specific T cell populations return to a tolerant state ([@R44]). We tested whether additional antigenic stimulation could continue to expand OTI cells. Secondary infection (2°) with *Listeria monocytogenes*-Ova (LM-Ova) and tertiary infection (3°) with vaccinia virus-Ova (VV-Ova) yielded an \~700-fold expansion of OTI in iFABP-Ova mice by day 7 after the last infection, compared to the starting, tolerant OTI population ([Figure 1C](#F1){ref-type="fig"}). OTI numbers increased in the spleen, mesenteric lymph node (mLN), and small intestinal intraepithelial lymphocytes (IELs) ([Figure 1D](#F1){ref-type="fig"}). Not only was proliferation of OTI cells induced but interferon γ (IFN-γ) and tumor necrosis factor α (TNF-α) production was also restored ([Figures 1A](#F1){ref-type="fig"}, [1E](#F1){ref-type="fig"}, and [S2](#SD1){ref-type="supplementary-material"}) ([@R32]; [@R37]). Therefore, dysfunction is reversible for high-affinity tolerant CD8 T cells through antigen-driven signals, and the resulting population is functional and can continue to be expanded.

Self-Specific T Cell Expansion Results in Avidity Maturation but Not Sustained Autoimmunity {#S4}
-------------------------------------------------------------------------------------------

To determine whether intestinal autoimmunity was induced after tolerance reversal in OTI cells, weight loss was measured in iFABP-Ova mice ([@R56]). All of the mice maintained or gained weight after 3° infection ([Figure 1F](#F1){ref-type="fig"}). Serum iFABP concentration is used both in animal models and in the clinic to indicate small intestinal damage ([@R11]). We found a basal level of serum iFABP in iFABP-Ova mice with anergic OTI (tolerant OTI versus no OTI) ([Figure S2](#SD1){ref-type="supplementary-material"}). At day 0 of 3° infection, there is little iFABP in the serum, indicating no ongoing autoimmunity (3° day 0). By day 10 after 3° infection, serum iFABP was increased, despite little weight loss. This was a transient increase in serum iFABP, as levels were back to baseline by day 30 after 3° ([Figure S2](#SD1){ref-type="supplementary-material"}). This is similar to previously published results indicating that self-reactive CD8 T cells do not necessarily induce pathology in antigen-bearing non-malignant tissue after tolerance reversal ([@R32]). Ultimately, strong antigenic stimulation can induce the expansion of high-affinity self-specific CD8 T cells, resulting in tissue migration and induction of effector functions.

Avidity maturation has been shown to be critical for the expansion of self-specific T cells ([@R1]; [@R59]). Tolerance reversal of OTI cells was correlated with increased K^b^-SIINFEKL tetramer geometric mean fluorescence intensity (GMFI) after each infection ([Figures 1G](#F1){ref-type="fig"} and [1H](#F1){ref-type="fig"}). This indicated that TCR levels and antigen sensitivity is enhanced with each stimulation. TCR avidity was correlated with increased PD-1 expression ([Figure 1I](#F1){ref-type="fig"}). This is reminiscent of avidity maturation that occurs in self-specific CD8 T cells as they participate in autoimmune diabetic pathology or tumor control ([@R1]; [@R59]). Thus, increased antigen sensitivity is a characteristic of T cells undergoing tolerance reversal.

Incomplete Negative Selection of Endogenous Self-Specific CD8 T Cells {#S5}
---------------------------------------------------------------------

We showed that established peripheral CD8 T cell tolerance can be overcome with iterative stimulation in iFABP-Ova mice. We then tested whether the same would be true for endogenous self-specific CD8 T cells. In iFABP-Ova mice, Ova is expressed via AIRE and K^b^-SIINFEKL-specific CD8 T cells are subject to both central and peripheral tolerance ([@R22]; [@R56]). Endogenous K^b^-SIINFEKL-specific CD8 T cell responses are not observed after infection with single Ova-bearing vectors, indicating that either negative selection is robust or T cell tolerance is established ([Figure 2A](#F2){ref-type="fig"}). However, low-affinity self-specific T cells can escape negative selection ([@R13]; [@R61]). As sequential infections were effective at generating ex-tolerant OTI, we hypothesized that one round of vaccination was insufficient to break tolerance for endogenous self-specific CD8 T cells. This is in line with studies showing that two rounds of vaccination were required to precipitate CD8 T cell-mediated diabetes, although these T cells could not be detected with major histocompatibility complex class I (MHC I) tetramers ([@R13]). When LM-Ova was given as a 2° to iFABP-Ova mice, very few self-specific CD8 T cells were detected ([Figure 2B](#F2){ref-type="fig"}). However, when 3° with VV-Ova was given, a significant population of self-specific CD8 T cells arose ([Figure 2C](#F2){ref-type="fig"}). This population was below the level of detection when VV-Ova was given alone as an initial infection (1°) ([Figure 2A](#F2){ref-type="fig"}). By day 30 after 3°, the K^b^-SIINFEKL self-specific CD8 T cells accounted for as much as 60% of total CD8 T cells in self-antigen-bearing mice ([Figure 2D](#F2){ref-type="fig"}). We noted greater variability in the K^b^-SIINFEKL-specific CD8 T cell burst size in iFABP-Ova versus C57BL/6 mice ([Figure 2D](#F2){ref-type="fig"}). This is likely due to the numerical variance of K^b^-SIINFEKL-specific CD8 T cell precursors in iFABP-Ova mice, a result of negative selection. The expansion of self-specific CD8 T cells was not an artifact of priming recent thymic emigrants, as similar T cell responses were observed in mice that were thymectomized before 1 ° vaccination ([Figure 2E](#F2){ref-type="fig"}). These data indicate that negative selection is incomplete, and despite tolerance mechanisms, a population of self-specific CD8 T cells exists within the endogenous repertoire that can be expanded.

Robust Stimulation of Self-Specific CD8 T Cells Induces Functional Changes {#S6}
--------------------------------------------------------------------------

We interrogated the functional and phenotypic characteristics of K^b^-SIINFEKL-specific CD8 T cells expanded under self- and non-self-conditions. The expressions of PD-1 and granzyme B by K^b^-SIINFEKL-specific CD8 T cells in iFABP-Ova and C57BL/6 are not significantly different ([Figure 3A](#F3){ref-type="fig"}). The PD-1^lo^ phenotype was expected in C57BL/6 animals, as the vectors are short-lived and antigen is quickly cleared. However, PD-1^lo^ expression was unexpected in iFABP-Ova mice, as Ova self-antigen is persistently presented on MHC I ([@R22]; [@R32]; [@R37]; [@R55]; [@R56]). The PD-1^lo^ phenotype on endogenous K^b^-SIINFEKL-specific CD8 T cells is likely due to low TCR affinity and suboptimal signaling to induce PD-1 ([@R19]). The self-specific CD8 T cell population has a lower GMFI of Kb-SIINFEKL tetramer binding compared to the non-self-population, indicating lower TCR affinity ([Figure 3B](#F3){ref-type="fig"}). MHC tetramers for vector epitopes (N and B8R) show similar GMFIs between C57BL/6 and iFABP-Ova ([Figure 3B](#F3){ref-type="fig"}). After iterative immunizations, K^b^-SIINFEKL CD8 T cells in iFABP-Ova mice produced cytokines upon peptide stimulation and had cytotoxic function *in vivo* ([Figures 3C](#F3){ref-type="fig"} and [3D](#F3){ref-type="fig"}). Despite reactivity to self-antigen by functional assays, autoimmunity was not observed in the small intestine ([Figure S3B](#SD1){ref-type="supplementary-material"}) ([@R32]; [@R55]). Ultimately, self-specific CD8 T cells are functional relative to population expansion size and are not necessarily pathogenic ([Figures 3A](#F3){ref-type="fig"}--[3D](#F3){ref-type="fig"} and [S3](#SD1){ref-type="supplementary-material"}).

Tolerance Reversal Is Coupled to Antigen-Driven Avidity Maturation {#S7}
------------------------------------------------------------------

It was striking that the expansion of self-specific CD8 T cells after 3° was greater than 1° responses in C57BL/6 mice ([Figures 2D](#F2){ref-type="fig"} and [2E](#F2){ref-type="fig"}). We hypothesized that K^b^-SIINFEKL-specific CD8 T cells were present and responsive before 3° immunization in iFABP-Ova mice, despite a lack of detection via MHCI tetramers ([Figure 2](#F2){ref-type="fig"}) [@R16]). We examined the self-specific responses in iFABP-Ova mice after 1° and 2° using cytokine production as a readout after *ex vivo* peptide stimulation. With this method, K^b^-SIINFEKL-specific CD8 T cells were readily visualized after 2° in iFABP-Ova mice, despite being very rare via MHC I tetramer staining ([Figures 2B](#F2){ref-type="fig"} and [3C](#F3){ref-type="fig"}). We found that the number of K^b^-SIINFEKL-specific CD8 T cells differed significantly between the two detection methods ([Figure 3E](#F3){ref-type="fig"}). The number of T cells detected via cytokine production in iFABP-Ova animals at 2° was equivalent to the number of MHC I tetramer-binding cells in C57BL/6 animals after 1° ([Figures 3E](#F3){ref-type="fig"} and [3F](#F3){ref-type="fig"}). Therefore, the lack of MHC I tetramer-binding cells at 2° was not due to low numbers, as tetramers easily detected equivalent numbers of non-self-specific CD8 T cells ([Figures 3E](#F3){ref-type="fig"} and [3F](#F3){ref-type="fig"}, dotted line). When the number of self-specific CD8 T cells at 2° was normalized to the number of cytokine producers in B6 1° mice, the same trend was observed ([Figure S3C](#SD1){ref-type="supplementary-material"}). Thus, low-affinity self-specific CD8 T cells are underrepresented by MHC I tetramers before 3° immunization.

We hypothesized that multiple immunizations enhanced MHC I tetramer binding and increased functional avidity. To test this, we evaluated functionality in a peptide dose-response curve before and after 3°. Before 3°, cytokine production was suboptimal in self-specific CD8 T cells, as compared to non-self-specific T cells ([Figures 3G](#F3){ref-type="fig"} and [S3A](#SD1){ref-type="supplementary-material"}). However, after 3°, self-specific T cells produced significantly more IFN-γ than at 2°. When the *in vivo* killing capacity was normalized to antigen-specific T cell numbers, this function increased from 1° to 3° ([Figure S3B](#SD1){ref-type="supplementary-material"}). This demonstrates a greater sensitivity to antigen for endogenous self-specific CD8 T cells after 3° vaccination, establishing avidity maturation as a corollary of iterative stimulation.

Repeated Stimulation Induces Cell-Intrinsic Changes in Self-Specific CD8 T Cells with Memory T Cell Characteristics {#S8}
-------------------------------------------------------------------------------------------------------------------

Self-specific T cells can be rendered non-responsive through both cell-intrinsic and cell-extrinsic factors ([@R30]). To determine whether tolerance reversal is a result of environmental or T cell-intrinsic changes, splenocytes from 2° immunized mice were transferred into antigen-matched naive hosts ([Figure 4A](#F4){ref-type="fig"}). At transfer, very few K^b^-SIINFEKL-specific CD8 T cells were detectable via MHC I tetramers in iFABP-Ova mice ([Figure 2](#F2){ref-type="fig"}). Recipient mice were infected with VV-Ova, which alone does not induce MHC I tetramer-binding T cells in iFABP-Ova mice ([Figure 2A](#F2){ref-type="fig"}). After just one infection, iFABP-Ova donor-derived tetramer-binding self-specific CD8 T cells were detectable at high levels in new hosts ([Figure 4A](#F4){ref-type="fig"}). Thus, tolerance reversal caused by sequential antigenic stimulation leads to cell-intrinsic changes in self-specific CD8 T cells.

Classical memory CD8 T cells do not require continued antigenic stimulation for their survival ([@R31]). However, chronically stimulated T cells become antigen addicted and do not survive in antigen-free hosts ([@R58]). To determine whether expanded self-specific CD8 T cells have the characteristics of memory or exhausted cells, we asked whether these T cells could survive long term in an antigen-free host. Equal numbers of boosted K^b^-SIINFEKL-specific CD8 T cells were transferred from 3° iFABP-Ova mice to naive C57BL/6 or iFABP-Ova hosts. Similar numbers of donor-derived K^b^-SIINFEKL self-specific CD8 T cells were recovered from antigen-free and antigen-bearing hosts 70 days after cell transfer ([Figure 4B](#F4){ref-type="fig"}). Therefore, antigen is not needed to maintain expanded self-specific CD8 T cells, similar to traditional memory CD8 and CD4 T cells ([@R31]; [@R52]).

Self-specific CD8 T cell activation has been shown to occur via dual TCR expression, in which virus-specific TCRs are activated on T cells also bearing self-reactive TCR ([@R18]). To test whether this occurred here, we performed dual-MHC I tetramer staining on CD8 T cells in iFABP-Ova animals after 3°. K^b^-SIINFEKL-specific CD8 T cells did not bind MHC I tetramers complexed to vaccinia virus (B8R) nor to VSV (N) immunodominant epitopes ([Figure 4C](#F4){ref-type="fig"}). Thus, self-specific T cell response is not attributed to activation through an alternative TCR.

Sequential Infections Are More Robust Than a Persistent Infection at Potentiating Self-Specific CD8 T Cell Responses {#S9}
--------------------------------------------------------------------------------------------------------------------

We have shown that multiple antigenic encounters are necessary for the expansion of self-specific CD8 T cells. However, persistent infections such as murine cytomegalovirus (MCMV) can also drive large CD8 T cell responses ([@R49]). To test whether a persistent infection producing self-antigen could substitute for multiple acute infections, we gave C57BL/6 and iFABP-Ova mice MCMV-Ova. By day 50 post-infection, 0.2% of CD8 T cells were K^b^-SIINFEKL specific in iFABP-Ova hosts, and this increased to \~1% by day 150 ([Figures 4D](#F4){ref-type="fig"} and [4E](#F4){ref-type="fig"}). However, MCMV-Ova infection did not recapitulate the expansion of K^b^-SIINFEKL CD8 T cell achieved with 3 rounds of acute infection (\~60% of CD8 T cells) ([Figure 2D](#F2){ref-type="fig"}). MCMV-Ova infection did not expand absolute cell numbers, with \~1 × 10^4^ K^b^-SIINFEKL-specific CD8 T cells, compared to \~1 × 10^6^ after multiple immunizations ([Figures 3D](#F3){ref-type="fig"} and [4E](#F4){ref-type="fig"}). Similar numbers of vector (M45)-specific CD8 T cells were detected between groups ([Figure 4E](#F4){ref-type="fig"}). There were significant differences in the IE3-specific CD8 T cells between iFABP-Ova and C57BL/6 mice, suggesting compensation for the blunted K^b^-SIINFEKL response in iFABP-Ova animals. Overall, these data demonstrate that sequential immunization is superior to MCMV as a method to expand self-specific CD8 T cells.

Expansion of Melanocyte-Specific Circulating and Resident Memory T Cells {#S10}
------------------------------------------------------------------------

Tolerance to Ova self-antigen is robust in endogenous and adoptive transfer models, but Ova is not a naturally occurring self-antigen. In both mice and humans, the melanocyte protein gp100 is a self-antigen expressed in the skin and is a tumor-associated antigen in melanoma ([@R20]; [@R35]). Previous studies suggested that melanoma tumor-specific T cell responses can be enhanced via a heterologous prime boost vaccination ([@R9]; [@R17]). We tested whether our sequential immunizations could reverse tolerance for endogenous gp100-specific CD8 T cells in C57BL/6 mice. A single vaccination with VSV-gp100 was insufficient to expand a detectable population of D^b^-gp100-specific CD8 T cells ([Figure 5A](#F5){ref-type="fig"}). However, multiple immunizations with gp100-producing vectors expanded a large population of skin-specific CD8 T cells ([Figure 5A](#F5){ref-type="fig"}). The mouse gp100 epitope is thought to have a lower affinity for mouse MHC I than the human gp100 epitope ([@R35]). After 3°, gp100-specific CD8 T cells are functional and equivalently recognize both the mouse and human D^b^-gp100 epitopes ([Figure S4A](#SD1){ref-type="supplementary-material"}--[S4C](#SD1){ref-type="supplementary-material"}). We observed avidity maturation of the endogenous gp100 antigen-specific T cell pool after boosting, as the GMFIs of tetramer staining increased after 3° ([Figure 5B](#F5){ref-type="fig"}). Multiple gp100-specific CD8 T cell clones responded to immunization; at least seven different Vβ chains were detected in the gp100-specific T cell pool ([Figures 5C](#F5){ref-type="fig"} and [S4D](#SD1){ref-type="supplementary-material"}). Multiple tolerant T cells are mobilized, and the response is not due to the outgrowth of a single high-affinity clone.

We investigated the NLT distribution of expanded D^b^-gp100-specific CD8 T cells. Immunization with gp100 vectors induced widespread dissemination of D^b-^-gp100-specific CD8 T cells to lymphoid and NLTs, such as the skin, brain, and lung ([Figures 5D](#F5){ref-type="fig"} and [5E](#F5){ref-type="fig"}). The location of these self-specific T cells in tissue parenchyma versus tissue vasculature was confirmed via intravenous (i.v.) antibody staining ([@R2]). The cells in NLT share a common Vβ repertoire, indicating that they originated from common precursors ([Figure 5F](#F5){ref-type="fig"}). The majority of self-specific CD8 T cells in NLTs have a high expression of PD-1, yet many cells in the skin make IFN-γ, albeit to a lower degree compared to secondary lymphoid organ (SLO) cells ([Figures 5E](#F5){ref-type="fig"}, [S4E](#SD1){ref-type="supplementary-material"}, and [S4F](#SD1){ref-type="supplementary-material"}). Despite the functionality of gp100-specific CD8 T cells, autoimmune pathology was not observed in the skin ([Figure S4G](#SD1){ref-type="supplementary-material"}). In all of the model systems investigated, functionality to self-antigens can be observed in boosted CD8 T cell populations without concomitant autoimmunity.

Tissue Residency in Expanded Populations of Self- and Non-self-Specific CD8 T Cells {#S11}
-----------------------------------------------------------------------------------

We showed that expanded self-specific CD8 T cells share some characteristics with non-self-specific memory CD8 T cells. To directly compare boosted self- and non-self-specific CD8 T cells in intact hosts, we used a dual antigen-boosting method. C57BL/6 mice were immunized with both gp100- and Ova-producing vectors simultaneously. Boosted self- and non-self-specific CD8 T cell populations were found in all of the analyzed organs ([Figure S5A](#SD1){ref-type="supplementary-material"}). The number of self-specific and foreign antigen-specific CD8 T cells were similar in many tissues, such as skin, lung, liver, and mLN, but differed in the salivary gland, female reproductive tract (FRT), brain, spleen, and inguinal LN (iLN). Parabiosis surgery was performed on dual-immunized mice to delineate the number of T~RM~ that are induced after sequential immunization. The majority of D^b^-gp100-specific and Ova-specific CD8 T cells found in tissues are T~RM~ ([Figure 5G](#F5){ref-type="fig"}).

Multiple immunizations increased the percent residence, as compared to a 1° response, in tissues such as small intestine, skin, lung, and liver ([Figure 5G](#F5){ref-type="fig"}, striped versus gray bars). This is also true for mLNs and potentially other SLOs. These data are in line with previously published results indicating that CD8 T cells are resident in many tissues and that anamnestic responses in NLT drive increased T~RM~ deposition in SLO ([@R4]; [@R24]; [@R41]; [@R50]; [@R57]). Both self- and foreign antigen-specific CD8 T cells fail to conform to the CD69^+^CD103^+^ phenotype often assigned to T~RM~ ([Figure S6](#SD1){ref-type="supplementary-material"}) ([@R24]; [@R41]). Our data demonstrate the versatility of heterologous prime-boost-boost for the expansion of both self- and foreign antigen-specific CD8 T cells and the potential for inducing large numbers of T~RM~ in SLOs and NLTs.

Expanded Self-Specific CD8 T Cells Control Aggressive Tumor Growth {#S12}
------------------------------------------------------------------

We next examined whether the expansion of D^b^-gp100 CD8 T cells could be used to control the growth of melanoma tumors. Mice were challenged with an aggressive mouse-derived B16 melanoma cell line that produces gp100. The amount of gp100 produced in tumors is \~100-fold compared to healthy adjacent skin, which is similar to melanoma in humans ([Figure S5H](#SD1){ref-type="supplementary-material"} and [S5I](#SD1){ref-type="supplementary-material"}) ([@R54]). The amount of gp100 produced per cell is higher in tumors, likely leading to more MHC-I:gp100 complexes, as compared to healthy skin ([Figure S5I](#SD1){ref-type="supplementary-material"}). The lack of autoimmunity in boosted mice may be controlled by lower antigen levels in healthy tissue. In naive mice challenged with B16 tumors, 100% of mice develop tumors by day 8 and *de novo* D^b^-gp100-specific responses are not detected within tumors ([Figures 6A](#F6){ref-type="fig"} and [6B](#F6){ref-type="fig"}). This is in contrast to B16-Ova tumors, which can induce the activation of K^b^-SIINFEKL-specific CD8 T cells ([Figure 6A](#F6){ref-type="fig"}). Mice immunized with 1° VSV-gp100 were given 2° vaccination 2 days before B16 challenge and demonstrated delayed tumor incidence, as well as control of tumor growth and size ([Figure 6B](#F6){ref-type="fig"}). The growth delay was accompanied by robust gp100-specific CD8 T cell infiltration into tumors ([Figure 6C](#F6){ref-type="fig"}). Tumor-infiltrating lymphocytes were functional and produced cytokines in response to antigen. Because D^b^-gp100-specific CD8 T cells were PD-1^hi^, we tested whether this level of protection could be enhanced by the addition of anti-PD-L1 blockade therapy. However, anti-PD-L1 given at the time of vaccination did not enhance protection from the B16 challenge over 2° vaccination alone ([Figures 6D](#F6){ref-type="fig"} and [S5B](#SD1){ref-type="supplementary-material"}). Effector self-specific T cells at 2° were sufficient to delay tumor onset, but they were not potentiated by PD-L1 blockade.

We then tested the therapeutic potential of gp100-specific CD8 T cells to delay ongoing tumor growth. B16 cells were injected into naive, 2° Ova-boosted or 2° gp100-boosted C57BL/6 mice. At day 8 after B16 injection, when tumors were palpable in all of the mice, 2° mice received the third immunization with either adenovirus (Ad)-gp100 or Ad-Ova. Naive mice remained unimmunized. Gp100 therapeutically vaccinated animals better controlled tumor growth ([Figure 6E](#F6){ref-type="fig"}). At 18 days after vaccination, tumor size was reduced by \~61% compared to controls ([Figure S5C](#SD1){ref-type="supplementary-material"}). The effect was CD8 T cell mediated, as tumor growth was not controlled when CD8 T cells were depleted during vaccination ([Figure S5D](#SD1){ref-type="supplementary-material"}). Thus, therapeutic vaccination targeting self-specific CD8 T cells can delay malignant cell growth for established tumors.

Previous studies stressed the importance of neo-antigen-specific T cell responses in tumor control ([@R46]). To determine whether combination immunotherapy generating both self- and neo-antigen-specific CD8 T cell responses could increase anti-tumor efficacy, we compared the anti-tumor potential of single- and dual-boosted mice. gp100 (self-Ag)- and Ova (neo-Ag)-specific T cell populations in C57BL/6 mice were generated by 3° immunizations. At day 2 after the final infection, single- and dual-antigen-boosted mice were challenged with B16-Ova melanoma tumors, which produce both gp100 (self) and Ova (neo) antigens. While single-boosted (Ova or gp100) T cell populations were able to delay tumor onset and protect 25%--30% of mice, the anti-tumor benefit was greatest for dual-boosted mice ([Figure 6F](#F6){ref-type="fig"}). All (100%) of the dual-boosted mice remained tumor free for the duration of the study.

We predicted that synergism between self- and neo-antigen-specific T cell responses was responsible for increased tumor control in dual-boosted mice. This prediction was based on the paucity of total antigen-specific CD8 T cells in dual-boosted mice compared to single-boosted mice ([Figure S5E](#SD1){ref-type="supplementary-material"}). In the skin and SLOs, dual-boosted mice have fewer D^b^-gp100- and K^b^-SIINFEKL-specific CD8 T cells compared to their single-boosted counterparts. This may be linked to the decreased antigen load of each type during the dual-boosting process.

We showed that dual-boosting generated self- and neo-antigen-specific CD8 T cells in NLTs and SLOs ([Figures 5G](#F5){ref-type="fig"} and [S5A](#SD1){ref-type="supplementary-material"}). The activation of T~RM~ *in situ* has been shown to recruit circulating immune cells and enhance immune activation and function locally ([@R4]; [@R42]). As circulating D^b^-gp100-specific T cells are more functional than skin residents ([Figure S4E](#SD1){ref-type="supplementary-material"}), we hypothesized that self- and neo-antigen-specific CD8 T cells synergized by T~RM~ reactivation in the skin and inducing recruitment of circulating T cells. We tested the recruitment potential of skin T~RM~ in dual-boosted mice by tattooing the skin with cognate peptide---either gp100 or SIINFEKL. After *in situ* reactivation, K^b^-SIINFEKL-specific CD8 T cells efficiently recruited circulating memory CD8 T cells ([Figures 6G](#F6){ref-type="fig"} and [S5F](#SD1){ref-type="supplementary-material"}). Reactivated K^b^-SIINFEKL-specific T~RM~ recruited CD4 T and natural killer (NK) cells, increased granzyme B, and recruited circulating D^b^-gp100-specific cells ([Figures 6G](#F6){ref-type="fig"} and [S5G](#SD1){ref-type="supplementary-material"}). This is similar to the observation that the reactivation of virus-specific CD8 T cells within tumors can enhance tumor elimination ([@R40]). Therefore, both circulating and resident populations likely contribute to tumor control ([@R12]).

DISCUSSION {#S13}
==========

Our data show that established CD8 T cell tolerance is not absolute. Despite central and/or peripheral tolerance, responses to self- and shared tumor antigens can be elicited with sequential immunization targeting self-antigens *in vivo*. This method can generate functional self-specific CD8 T cells to different tissue-specific antigens. We show that even with AIRE-mediated negative selection, endogenous low-affinity self-specific CD8 T cells exist in the CD8 T cell repertoire. Multiple antigenic exposures drive antigen sensitization of self-specific CD8 T cells through avidity maturation, leading to MHC I tetramer binding, increased sensitivity to Ag, and expansion in peripheral blood, SLO, and NLT.

These data are supported by previous studies that demonstrated that transgenic, low-affinity self-specific CD8 T cells can escape negative selection in mice ([@R6]; [@R61]). We show that this is also true for endogenous self-specific CD8 T cells. We speculate that this would occur for many self-antigens. In humans, the negative selection of sex-specific CD8 T cells has been shown to be incomplete ([@R60]). Furthermore, rare CD8 T cells specific for shared self- and tumor-antigens can also be found within human colorectal tumors ([@R14]). Humans may harbor quiescent self-antigen-specific CD8 T cells, which could be exploited for immunotherapy.

Comparing tolerance to Ova in iFABP-Ova mice with gp100 in C57BL/6 mice, it is apparent that not all self-specific CD8 T cell responses are equal. While immunization enhanced both populations, the minimum number of boosting events differed. iFABP-Ova mice required three vaccinations and gp100 only two to observe self-specific T cell responses ([Figures 2](#F2){ref-type="fig"} and [5](#F5){ref-type="fig"}). We hypothesize that the difference observed in the two model systems might be due to variable T cell precursor frequency and TCR affinity ([@R39]). The amount of antigen expressed in the thymus is important in determining precursor numbers ([@R47]). The density of MHC I-Ova complexes in iFABP-Ova mice and MHC I-gp100 in C57BL/6 mice may differ, and the amount of self-antigen expressed may vary between individuals. This could explain the variability in T cell burst size after 3° vaccination in iFABP-Ova mice ([Figure 2D](#F2){ref-type="fig"}). Differences in PD-1 expression in each system may also be linked to TCR affinity ([@R19]). We suspect that CD8 T cell tolerance to self-antigens and dysfunction in many contexts could be readily reversed, but the number of robust boosting events required to do this would vary because of precursor number and TCR affinity differences, which are influenced by the location and density of self-antigens.

Our data show that cumulative antigenic experience is key for the expansion of self-specific CD8 T cell populations and reversal of tolerance. Cell-intrinsic changes occur that allow self-specific T cells to bind MHC I tetramers, produce cytokines, and participate in antigen-specific killing. This type of population-level avidity maturation is key for the development of autoimmune diabetes and anti-tumor immunity ([@R1]; [@R7]; [@R48]; [@R59]). These data suggest that increased antigen sensitivity is characteristic of T cells overcoming tolerance.

We have shown that with sequential immunization, self-antigens can be very immunogenic, and this method can generate large numbers of self-specific CD8 T cells. After 3° in iFABP-Ova mice, \~6 × 10^5^ tetramer-binding self-specific CD8 T cells can be isolated from the spleen alone. This is an underestimate of the total self-specific CD8 T cell response, as antigen-specific T cells are found in other locations, and additional K^b^-SIINFEKL-specific CD8 T cells are detectable with cytokine assays ([Figure 3E](#F3){ref-type="fig"}). In naive C57BL/6 mice, the K^b^-SIINFEKL precursor pool consists of \~125 cells ([@R34]). The starting frequency of K^b^-SIINFEKL precursors in unmanipulated iFABP-Ova mice is unknown: it will likely be less than in C57BL/6 mice because of negative selection. Assuming no decrease in the precursor frequency in iFABP-Ova mice, the population of self-specific CD8 T cells expanded \~5,000 times based on MHC I tetramer counts and \~28,000 times based on cytokine counts ([Figure 3E](#F3){ref-type="fig"}). gp100-specific CD8 T cell responses can also be as robust as foreign antigen-specific CD8 T cells, as demonstrated by the similar number of T cells in dually immunized mice ([Figure S5A](#SD1){ref-type="supplementary-material"}). This demonstrates that self-antigens are not necessarily poorly immunogenic, but that immunization methods need to be robust and iterative to generate T cell responses to self.

We found that repeated immunizations with acute vectors are critical for tolerance reversal and cannot be replaced by a chronic infection, such as MCMV ([Figure 4D](#F4){ref-type="fig"}). The rest period between immunizations may be crucial for the optimal expansion of self-specific CD8 T cells, as it is for foreign antigen-specific CD8 T cells ([@R53]). This is likely important for the establishment of classical memory T cell characteristics, such as antigen-independent survival ([Figure 4B](#F4){ref-type="fig"}) ([@R31]; [@R52]).

This immunization regimen resulted in the widespread dissemination of self-specific CD8 T cells. Promiscuous seeding of numerous host organs is well established for foreign antigen-specific CD8 T cells ([@R26], [@R27]). Here, we show that OTI and melanocyte-specific T cells accumulated in all of the NLTs and SLOs that were analyzed ([Figures S1](#SD1){ref-type="supplementary-material"} and [S5A](#SD1){ref-type="supplementary-material"}). In fact, the majority of boosted D^b^-gp100-specific CD8 T cells were T~RM~ ([Figure 5G](#F5){ref-type="fig"}). Proportionally, T~RM~ frequency is enhanced in the lung, liver, and small intestine after 3°. This is similar to what has been shown for sequential immunizations in the skin and may be particularly important for these organs, as they are highly vascularized and often sites of cancer metastases ([@R10]). Our immunization regimen also showed a trend toward increasing CD8 T~RM~ in SLOs ([@R43]; [@R54]). This may be particularly important for cancer immunotherapy, as having cancer-specific T cells patrol LNs would be beneficial for metastasis control. The sufficiency of endogenously derived self-specific T~RM~ to control tumors bearing self-antigens warrants further investigation.

T~RM~ generated with multiple immunizations do not conform to the canonical CD69^+^CD103^+^ T~RM~ phenotype ([@R24]; [@R50]). Many self-specific T~RM~ express CD69, but expression varies across tissues. CD103 expression is lower in self-specific CD8 T cells compared to foreign antigen-specific CD8 T cells in the same tissues ([Figure S6](#SD1){ref-type="supplementary-material"}). CD103 downregulation may be linked to the frequency of antigen encounter and is not necessarily directly linked to tissue residency ([@R8]). This distinction is important, especially when examining human T~RM~, which rely on phenotypic markers for classification. Our parabiosis data demonstrate that many self-specific CD8 T cells in intestinal and reproductive mucosal tissues are CD103^−^ and some lack CD69. A re-examination of T~RM~ designation based on phenotypic markers is imminently needed.

These data also have important ramifications for cancer immunotherapy. Several groups have demonstrated that T~RM~ are crucial for effective tumor control and are correlated with increased survival ([@R12]; [@R25]; [@R33]). Here, we show that melanocyte-specific CD8 T cells expanded through iterative immunization slow the growth of aggressive melanoma tumors in a therapeutic or prophylactic setting ([Figure 6](#F6){ref-type="fig"}). The expansion of self-specific CD8 T cells did not result in pathology in healthy tissue. This is likely due to the difference in the amount of self-antigen produced in tumor tissue as compared to healthy tissue, yielding more MHC I-peptide complexes for CD8 T cells to engage when in tumors ([Figures S5H](#SD1){ref-type="supplementary-material"} and [S5I](#SD1){ref-type="supplementary-material"}). While D^b^-gp100-specific CD8 T cells within tumors make IFN-γ and TNF-α, tumors are not always completely eliminated. However, additional rounds of immunization combined with concurrent boosting of neo-antigen-specific CD8 T cells resulted in 100% tumor clearance ([Figure 6F](#F6){ref-type="fig"}). The synergism observed between self- and neo-antigen-specific populations is not due to increased total tumor-specific cell numbers, as dual-boosted mice have fewer antigen-specific T cells compared to single-boosted mice. Upon *in situ* reactivation, K^b^-SIINFEKL-specific CD8 T cells in the skin recruit and activate circulating immune cells ([Figures 6G](#F6){ref-type="fig"}. [S5F](#SD1){ref-type="supplementary-material"}, and [S5G](#SD1){ref-type="supplementary-material"}). We hypothesize that neo-antigen-specific CD8 T cells synergize with self-specific populations by recruiting circulating tumor-reactive immune populations and generating a tumoricidal microenvironment ([@R42]). It is possible that targeting two tumor antigens prevents immune escape; however, the mutational landscape of B16-Ova tumors has not been explored in this context. These data show that self-specific CD8 T cells are an unrealized target for cancer immunotherapy and that these T cells can maximize anti-tumor responsiveness if complimenting neo-antigen-specific T cell responses ([@R23]; [@R46]).

Heterologous prime-boost-boost could be used to reinvigorate dysfunctional tumor neo-antigen-specific CD8 T cells as well. Tolerant OTI in iFABP-Ova mice are very similar to dysfunctional tumor antigen-specific CD8 T cells ([Figure 1](#F1){ref-type="fig"}) ([@R32]; [@R37]; [@R55]; [@R56]). We have shown that tolerized OTI cells are resistant to single or combination checkpoint therapy, yet the immunization regimen presented here can induce expansion and functionality in these OTI ([Figure 1](#F1){ref-type="fig"}) ([@R32]; [@R37]). Our data demonstrate that tolerant CD8 T cells resistant to checkpoint blockade can be rendered functional with robust, iterative antigenic stimulation and imply that this could activate T cells in cancer patients who do not respond to current immunotherapies.

Ultimately, tolerance to self-antigens can be overcome with repeated and robust antigen stimulation *in vivo*. Even dysfunctional high-affinity self-specific CD8 T cells resistant to checkpoint blockade can be rendered functional. Immunization targeting self-antigen induces T cell-intrinsic changes that confer improved antigen sensitivity and function with the deposition of large numbers of T~RM~ throughout the body. The robust expansion of host-specific CD8 T cells that recognize both self- and tumor antigens has therapeutic implications. We demonstrate that self-antigens are not necessarily poorly immunogenic, and their use as a cancer immunotherapy does not necessarily mean that autoimmune disease will be established. Ultimately, self-specific CD8 T cell populations are more dynamic and propitious than has been previously appreciated.

STAR★METHODS {#S14}
============

LEAD CONTACT AND MATERIALS AVAILIBILITY {#S15}
---------------------------------------

Information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Vaiva Vezys (<vvezys@umn.edu>). This study did not generate any unique reagents.

EXPERIMENTAL MODEL AND SUBJECT DETAILS {#S16}
--------------------------------------

### Mice {#S17}

C57BL/6J/CD45.2 (B6), B6.SJL-*Pfprc^a^ Pepc^b^*/BoyJ (45.1), and B6.PL-*Thy1^a^*/CyJ (B6 Thy1.1) mice were purchased from the Jackson Laboratory. OTI 45.1, OTI Thy1.1, P14, iFABP-Ova 45.2, and iFABP-Ova 45.1/45.2 mice were bred in our facility. Male and female mice were 6-12 weeks at the time of infection. Parabiosis studies only used female mice to prevent fighting. Littermates were randomly assigned into groups. All mice were used in accordance with University of Minnesota IACUC guidelines.

### Cell Lines {#S18}

Mycoplasma-free B16-F10 cells obtained from ATCC were expanded in RPMI 1640 with 10% FBS; 1% of the following: L-glutamine, penicillin/streptomycin, non-essential amino acids, and sodium pyruvate; and 1000× 2-mercaptoethanol. B16-Ova cells were obtained from B.J.B. and cultured similarly with the addition of G418 to maintain Ova expression. The sex of the B16-F10 or the B16-Ova cell lines is not known to us. Stocks were frozen and thawed at least 4 days prior to use. Cells were switched to DMEM containing media to induce melanin production at least 2 days prior to use.

METHOD DETAILS {#S19}
--------------

### Study Design {#S20}

The research objectives of this study were to: (a) determine the steps necessary to stimulate a CD8 T cell response to self-antigen and (b) evaluate whether self-specific CD8 T cells are found within non-lymphoid tissues and can participate in tumor control. We hypothesized that repeated infections with heterologous replicating vectors expressing self-antigen would stimulate tolerant self-specific CD8 T cells to expand and participate in tumor control. This controlled laboratory study used three established mouse models to monitor tolerance in a population of CD8 T cells specific for self-antigen expressed in the small intestine ([@R56]) and the skin ([@R12]; [@R25]; [@R33]). Mice were randomly assigned to treatment groups where necessary. Sample size and endpoints were determined based on previous studies showing biological effects ([@R19]; [@R25]). Data collection was terminated at pre-determined time points or when animal health or well-being was comprised, as determined by the University of Minnesota Institute for Animal Care and Use Committee (IACUC). All samples, including outliers, were included in the results.

### Infections {#S21}

Adult iFABP-Ova and B6 were immunized with 1×10^6^ PFU VSV-Ova i.v. (1°), 1×10^4^ CFU LM-Ova i.v. (2°), and/or 2×10^6^ PFU vaccinia virus (VV)-Ova i.v. (3°), with at least 30d between infections. The number of infections and infection type are indicated where necessary. Mice were immunized with MCMV-Ova i.p., as previously described ([@R49]). For gp100 2° immunizations, adult C57BL/6 mice were immunized with 1×10^6^ PFU VSV-gp100 i.v. (1°) ([@R15]) and 2×10^8^ PFU Ad2-gp100 ([@R51]) or Ad5-gp100 i.v (2°), with at least 30d between infections. For gp100 3° immunization, mice were given 1×10^6^ PFU VSV-gp100 i.v. (1°), 2×10^6^ PFU VV-gp100 i.v. (2°) and 2×10^8^ PFU Ad2-gp100 or Ad5-gp100 i.v (3°), with at least 30d between infections. For therapeutic vaccination experiments with Ova immunization, mice were given 1×10^6^ PFU VSV-Ova i.v. (1°), 2×10^6^ PFU VV-Ova i.v. (2°), and 2×10^8^ PFU Ad5-Ova i.v (3°). For dual infections with gp100 and OVA vectors, VSV was 1°, VV was used as 2° and Ad was used as a 3°, all i.v. Half the dose of the above stated amounts was used for all dual infections, except Ad, which was given at the full amount. For 1 ° OTI memory experiments, OTI were transferred to congenically disparate C57BL/6 mice and infected with 1×10^6^ PFU VSV-Ova i.v. the next day. For 1° P14 memory experiments, P14 were transferred to congenically disparate C57BL/6 mice and infected with 2×10^5^ PFU LCMV-Armstrong i.p. the next day

### Adoptive Transfers {#S22}

[Figure 4A](#F4){ref-type="fig"}: spleen and LN were harvested before 3° from iFABP-Ova/CD45.1/CD45.2 or B6/CD45.2 mice and incubated on plates coated with donkey-anti-mouse IgG F(ab')2 (H+L) and anti-CD4 (GK1.5) purified antibodies. Non-adherent cells were removed, washed, and transferred to naive iFABP-Ova/CD45.2 or B6/CD45.1 mice i.v. Mice were infected with VV-Ova 1d later.

[Figure 4B](#F4){ref-type="fig"}: 5×10^5^ K^b^-SIINFEKL-specific CD8 T splenocytes from 3° boosted iFABP-Ova/CD45.2 mice were transferred i.v. to naive iFABP-Ova/CD45.1/CD45.2 or B6/CD45.1 mice.

[Figures 1](#F1){ref-type="fig"},[5](#F5){ref-type="fig"}, [S1](#SD1){ref-type="supplementary-material"}, and [S2](#SD1){ref-type="supplementary-material"}: B6 memory OTI - 5×10^5^ naive OTI/CD45.1 or OTI/CD90.1+ splenocytes were transferred i.v. to C57BL/6/CD45.2 mice and infected the next day. OTI tolerance experiments: 5×10^5^ naive OTI/CD45.1 splenocytes were transferred i.v. to iFABP-Ova/CD45.2 mice or B6/CD45.2 mice and maintained for at least 30 days before sacrifice or infection for iFABP-Ova. B6 were infected within 2 days of OTI transfer because of naive T cell lifespan ([@R32]; [@R37]).

### Isolation of Lymphocytes, ELISA, and Flow Cytometry {#S23}

Lymphocytes from the spleen, LN, PBL, female reproductive tract (FRT), liver, lung, salivary gland (SG) and small intestinal intraepithelial layer were isolated as previously described ([@R50]). Brains were chopped and stirred 1h at 37°C with 100 U/mL type I collagenase (Worthington, Lakewood, NJ). All single cell suspensions were separated using 44/67% Percoll density gradients. Hair was removed from a 4cm^2^ abdominal skin section, chopped, and stirred in 2U/mL DNase, and 3mg/mL type III collagenase for 1h at 37°C ([@R24]). Tumors were chopped and stirred in 2U/mL DNase and 100U/mL type I collagenase for 15 m at 37°C. Tetramer pulldown was not performed on CD8 T cells, except for some data in [Figures 5B](#F5){ref-type="fig"} and [6A](#F6){ref-type="fig"}. Surface stains and intracellular stains were performed as previously described ([@R28]). Samples were acquired on an LSRII. Tissue and blood compartments were distinguished by i.v. injection of anti-CD8α antibody ([@R2]). Serum iFABP was measured by a Mouse iFABP ELISA Kit.

### Cytotoxicity and Cytokine Assays {#S24}

*In vivo* cytotoxicity assay: Naive splenocytes were labeled with 1 μM (Hi) or 100nM (Lo) CFSE ([@R3]). CFSE-Lo cells were pulsed with 1 μM SIINFEKL. Equal numbers of peptide-pulsed and non-pulsed cells were transferred i.v. to naive, 1° or 3° mice. 4h later, spleens were harvested. Percent killing calculation: 100-(\[(% peptide pulsed in boosted/% non-pulsed in boosted)/(% peptide pulsed in naive/% non-pulsed in naive)\]×100). For cytokine production, lymphocytes were incubated with 1 μg/mL GolgiPlug with or without 1 μg/mL peptide for OTI and gp100 experiments, 10-100 μg/mL peptide for endogenous Ova for 4h at 37°C.

### Thymectomy {#S25}

Adult mice were anesthetized and a lateral incision was made through skin and the top of the sternum to visualize the thymus. The thymus was extracted via vacuum and the wound was sutured. Animals recovered for 6 weeks before any other experimental procedures were performed.

### Histology {#S26}

Hematoxylin and eosin staining was performed on formalin fixed sections of small intestine. H&E staining was also performed on frozen skin sections. Sections were evaluated by a veterinary pathologist.

### Parabiosis {#S27}

Parabiosis surgery was done as described ([@R42]). Each mouse was shaved along the opposite lateral flank. Identical incisions were made on the lateral aspect of each mouse, and mice were conjoined via skin staples. Parabiosed mice were then allowed to rest for 14--30 days before sacrifice. Equilibration was confirmed in the peripheral blood prior to sacrifice. Percent residence formula: 100 × (1-((\# donor Ag-specific × 2)/(donor Ag-specific + host Ag-specific))).

### Tumor Challenges {#S28}

B6 mice were immunized and at day 2 after 2°, mice were challenged with 1×10^5^ B16/F10 or B16-Ova cells s.c. In prophylactic experiments, B16-Ova was given at day 2 after 2° or 3°. For therapeutic experiments, B16 cells were injected s.c. and at day 8 of B16 growth, when tumors were palpable, mice were (or were not) injected with Ad-Ova or Ad-gp100. For checkpoint blockade, anti-PD-L1 antibody was given at the time of the prophylactic vaccination, and then every 3 days at 200 μg i.p. for the duration of the tumor experiment. For CD8 depletion, anti-CD8 antibody was given after tumor challenge at 200 μg i.p. the day before therapeutic vaccination and at days 2 and 4.

### Skin Recruitment {#S29}

Skin recruitment was analyzed by tattooing 4 μg of indicated peptide in 50 μL volume at 20mm depth on shaved and depilated skin, and recruitment was assessed 48h later with the skin isolation protocol above. For recruitment of circulating memory cells, CD45.1 + memory P14 were enriched from the spleen 30 days after LCMV infection using CD8 negative selection and lymphocytes were transferred i.v. to dual-boosted hosts. The next day, hosts were tattooed with SIINFEKL orgp100 peptide. For recruitment of endogenous cell populations, dual-boosted mice were tattooed with SIINFEKL and gp100 on opposite flanks. For recruitment of D^b^-gp100-specific CD8 T cells, 3° gp100-boosted splenocytes were enriched for CD8 T cells and transferred to 3° dual-boosted mice, and the next day mice were tattooed with SIINFEKL peptide. Control depilation was done on contralateral side where indicated.

### Immunohistochemistry {#S30}

Frozen tumors with adjacent healthy skin were cut into 7 μm sections, mounted on glass slides, air-dried and fixed in acetone. Rabbit anti-mouse gp100 antibody was added after a blocking step, goat-α-rabbit Ig was used as the secondary antibody with a DAPI counterstain. Fluorescence was acquired on a Leica DM5500B 4 color fluorescent system with motorized z-focus stage for fully automated image stitching. Enumeration of gp100+ cells was done manually in ImageJ64. Representative areas in tumor and skin were selected and ImageJ64 software was used to enumerate DAPI+ nuclei ([@R50]). In the same image, gp100+ cells were determined by manual counting. To determine gp100 fluorescence per cell, a representative area on the tumor was selected and ImageJ64 software was used to calculate the integrated density and area of individual gp-100+ tumor cells. Similar gp-100 enumeration was done after selecting a representative area on the skin. Background readings of mean fluorescence were collected by selecting an area of the image where no cells were present. Corrected total cell fluorescence (CTCF) was calculated using this formula: CTCF = Integrated Density -- (Area of selected cell X Mean fluorescence of background reading).

QUANTIFICATION AND STATISTICAL ANALYSIS {#S31}
---------------------------------------

For bar graphs, error bars indicated ± SEM, except in [Figure 3](#F3){ref-type="fig"} where ± SD was used, as indicated. All samples were included, including outliers. For all figures, n refers to animal subjects, except [Figure S5I](#SD1){ref-type="supplementary-material"} top panel, where n refers to individual cells. Number of animals for each figure is indicated in the figure legend. Two-tailed t tests, Mann-Whitney U tests or Kruskal-Wallis H tests were performed where appropriate. Kaplan-Meier curves used Mantel-Cox test for significance. For all analyses, p values of less than 0.05 were considered significant. Star representation is indicated in figure legends.

DATA AND CODE AVAILIBILITY {#S32}
--------------------------

This study did not generate datasets/code.
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![Robust Immunization Overcomes Peripheral Tolerance of Dysfunctional High-Affinity Self-Specific CD8 T Cells\
(A) IFN-γ and TNF-α production by OTI from small intestine intraepithelial lymphocyte (IEL) compartment after *ex vivo* peptide stimulation. Left (tolerant): 60 days after adoptive transfer in iFABP-Ova hosts. Right (effector): day 7 after VSV-Ova in C57BL/6 hosts. Plots are gated on OTI.\
(B) iFABP-Ova mice were (+VSV-Ova) or were not (naive) infected with VSV-Ova 72 days after transfer of OTI. IELs were analyzed 359 days after OTI transfer. Plots are gated on i.v. negative CD8^+^ T cells. Numbers represent the frequency in gate.\
(C) OTI in PBL after day 0 of 1° (VSV-Ova) infection in B6 and iFABP-Ova mice. IFABP-Ova mice were infected 60 days after OTI transfer. B6 mice were infected 2 days after OTI transfer. The arrows indicate immunization (1° VSV-Ova; 2° LM-Ova; 3° VV-Ova). Solid black, B6; dashed gray, iFABP-Ova. Numbers, fold expansion of OTI at day 7 after 1° and day 7 after 3°, relative to day 0.\
(D) Number of OTI without infection (naive) and at days 30--40 post-3° in the IEL, spleen (SPL), and mLN. Filled, B6; open, iFABP-Ova; square, unimmunized; circle, after 3°. Numbers on graph, fold expansion from naive to 3°. Naive B6 IELs not included, as naive T cells are not found in NLTs.\
(E) IFN-γ and TNF-α production by splenic OTI 7 days after 3° in B6 and iFABP-Ova after *ex vivo* peptide stimulation. Plots are gated on OTI.\
(F) Weight of B6 and iFABP-Ova mice after 3°. Black, B6; red, iFABP-Ova.\
(G) Geometric mean fluorescence intensity (GMFI) of K^b^-SIINFEKL tetramer staining of OTI in PBLs of iFABP-Ova mice at indicated time points, normalized to wild type.\
(H) Histograms of K^b^-SIINFEKL tetramer staining of the OTI enumerated in (G). Black, B6 OTI. Red, iFABP-Ova OTI.\
(I) Correlation of GMFI of K^b^-SIINFEKL tetramer staining and GMFI PD-1 on OTI from iFABP-Ova mice day 6 after 3° in PBL. R^2^ value = 0.04275.\
Representative of at least 2 experiments totaling 3--10 animals per group. \*p ≤ 0.037, \*\*p ≤ 0.007, \*\*\*p ≤ 0.0002. Error bars indicate means ± SEMs.\
See also [Figures S1](#SD1){ref-type="supplementary-material"} and [S2](#SD1){ref-type="supplementary-material"}.](nihms-1542903-f0002){#F1}

![Sequential Immunization Induces Responsiveness in Endogenous Self-Specific CD8 T Cells\
(A) IFABP-Ova and B6 mice were infected with VSV-Ova, VV-Ova, or LM-Ova only. PBLs were analyzed 7 days later for K^b^-SIINFEKL-, K^b^-N-, or K^b^-B8R-specific CD8 T cells, or splenocytes were analyzed for I-A^b^-listeriolysin O (LLO)-specific CD4 T cells. N, B8R, and LLO epitopes from VSV, VV, or LM vector proteins. Gated on CD8 or CD4 T cells, respectively.\
(B) IFABP-Ova and B6 mice were infected with VSV-Ova and then LM-Ova 60 days later. I-A^b^-LLO-specific CD4 or K^b^-SIINFEKL-specific CD8 T cells were enumerated 7 days after LM-Ova. Top: splenocytes gated on CD4 T cells. Bottom: PBLs gated on CD8 T cells.\
(C--E) IFABP-Ova and B6 mice were infected with VSV-Ova, LM-Ova, and VV-Ova at least 40 days apart.\
(C) K^b^-SIINFEKL-specific CD8 T cells in PBLs of the same animal at the indicated times after VV-Ova (3°). Gated on CD8 T cells.\
(D) K^b^-SIINFEKL-specific CD8 T cells in PBLs were enumerated over the immunization period. Gray, iFABP-Ova; black, B6. Each line represents an individual.\
(E) K^b^-SIINFEKL-specific CD8 T cells in PBLs were enumerated as in (D) in adult mice thymectomized before 1°.\
Representative of at least 2 experiments totaling 5--12 animals per group.](nihms-1542903-f0003){#F2}

![Sequential Immunization Drives Avidity Maturation of Functional, Endogenous Self-Specific CD8 T Cells\
B6 or iFABP-Ova mice were subjected to Ova immunization.\
(A) PD-1 and granzyme B expression by K^b^-SIINFEKL-specific splenocytes 35 days post-3°. Histograms are gated on K^b^-SIINFEKL-specific CD8 T cells from iFABP-Ova (dashed) and B6 (solid) or CD44^lo^ CD8 T cells (gray filled).\
(B) GMFIs of indicated MHC I tetramer staining in splenocytes of iFABP-Ova (white) or B6 (black) mice at least 30 days after 3° VV-Ova.\
(C) Splenocyte IFN-γ and TNF-α production with *ex vivo* peptide stimulation ≥30 days after 1°, 2°, or 3°. Plots are gated on CD8 T cells.\
(D) *In vivo* killing of SIINFEKL-pulsed target cells 30 days post-1° or 3°. Black, B6; white, iFABP-Ova.\
(E) Enumeration of splenocytes binding K^b^-SIINFEKL tetramer or producing IFN-γ ≥30 days after 1°, 2°, or 3°. Black, tetramer^+^; white, IFN-γ. The dotted line represents CD8 T cells readily detectable in B6 at 1° with K^b^-SIINFEKL tetramers.\
(F) K^b^-SIINFEKL-specific CD8 T cell responses detected either with MHC I tetramer staining (Tet^+^) or cytokine assay (IFN-γ^+^) in iFABP-Ova mice after 2° as a function of K^b^-SIINFEKL tetramer-binding cells in B6 mice after 1°.\
(G) Percentage of maximum IFN-γ produced by splenic CD8 T cells ≥ 30 days after 2° or 3°. GMFI of IFN-γ production at 2° or 3° normalized to maximum GMFI of IFN-γ at matching time point. Black, B6; white, iFABP-Ova.\
Representative of at least 2 experiments totaling 4--12 animals per group. \*p \< 0.037, \*\*p ≤ 0.009, \*\*\*p ≤ 0.0006. Error bars indicate means ± SEMs, except in (B) where it is SDs.\
See also [Figure S3](#SD1){ref-type="supplementary-material"}.](nihms-1542903-f0004){#F3}

![Sequential Immunization Induces Cell-Intrinsic Changes in Self-Specific CD8 T Cells with Memory T Cell Characteristics\
(A) Splenocytes from iFABP-Ova or B6 mice before 3° were transferred into naive, congenically mismatched iFABP-Ova or B6, respectively. Host mice were infected with VV-Ova only. K^b^-SIINFEKL-specific donor and host cells were analyzed 30 days after VV-Ova in the spleen. Plots are gated on donor or host CD8 T cells.\
(B) Splenocytes from iFABP-Ova mice were transferred 30 days after 3° to naive, congenically mismatched iFABP-Ova or B6. Donor K^b^-SIINFEKL^+^ CD8 T cells were enumerated in spleen 70 days later.\
(C) iFABP-Ova or B6 splenocytes were stained with K^b^-SIINFEKL and K^b^-N tetramers in the same sample or K^b^-SIINFEKL and K^b^-B8R tetramers in the same sample 30 days after 3°. Plots are gated on CD8 cells.\
(D) K^b^-SIINFEKL tetramer-binding CD8 T cells were tracked in the PBLs of B6 or iFABP-Ova mice following MCMV-Ova. Black solid, B6; gray dashed, iFABP-Ova.\
(E) Numbers of K^b^-SIINFEKL, D^b^-M45, and K^b^-IE3 tetramer^+^ CD8 T cells were enumerated in the spleens of B6 or iFABP-Ova mice \>140 days post-MCMV-Ova infection. M45 and IE3 are MCMV proteins. Black, B6; white, iFABP-Ova.\
Representative of at least 2 experiments totaling 4--12 animals per group. \*\*\*p \< 0.0001. Error bars indicate means ± SEMs.](nihms-1542903-f0005){#F4}

![Sequential Immunization Breaks CD8 T Cell Tolerance to Skin-Specific Antigen and Generates Resident Memory T Cells in NLT and SLO\
(A--E) B6 mice were uninfected (naive) or infected with VSV-gp100 (1°), VV-gp100 (2°), and Ad5-gp100 (3°) at least 35 days apart.\
(A) PBLs were analyzed for D^b^-gp100-specific CD8 T cells at indicated times. Plots are gated on CD8 T cells.\
(B) GMFI of D^b^-gp100 tetramer staining from animals in (A).\
(C) Vβ expression after 2° and 3° in PBLs. Top: Average Vβ expression in D^b^-gp100 tetramer^+^ populations. Bottom: average Vβ expression in CD8^+^ D^b^-gp100 tetramer^−^ population at 3°.\
(D) Enumeration of D^b^-gp100-specific CD8 T lymphocytes in SPL, inguinal LN (iLN), skin, lung, and brain 110 days after 2° and 89 days after 3°. Black, 2°; red, 3°.\
(E) Lymphocytes from the skin, brain, and lung isolated from naive or gp100 3° immunized mice 30 days after 3°. Plots are gated on CD8 T cells.\
(F) Vβ expression after 3° in skin, brain, and lung. Top: average Vβ expression in CD8^+^ D^b^-gp100 tetramer^−^ populations. Bottom: Vβ expression in CD8^+^ D^b^-gp100 tetramer^+^ population.\
(G) Percentage residence for the indicated antigen-specific T cells. B6 mice were dual-boosted to generate both gp100- and SIINFEKL-specific CD8 T cells. Dual-boosted mice of different congenics were conjoined via parabiosis 35 days after 3°. To compare to 1° responses, B6 mice with congenically distinct memory OTI were conjoined to naive B6 mice. Black bars, 3° K^b^-SIINFEKL specific; striped bars, 3° D^b^-gp-100 specific; gray bars, 1° OTI memory.\
All data, except PBLs, based on i.v. negative T cells. Representative of at least 2 experiments totaling 3--12 animals per group. \*p \< 0.05 and p ≥ 0.01, \*\*p \< 0.01 and p \> 0.0001, \*\*\*p ≤ 0.0001. Error bars indicate means ± SEMs.\
See also [Figure S4](#SD1){ref-type="supplementary-material"}, [S5](#SD1){ref-type="supplementary-material"}, and [S6](#SD1){ref-type="supplementary-material"}.](nihms-1542903-f0006){#F5}

![Self-Antigen-Specific CD8 T Cells Targeting Tumor-Associated Self-Antigen Control Melanoma Growth\
(A) Visualization of antigen-specific CD8 T cells in tumors from unimmunized B6 mice. Left: frequency of D^b^-gp100-specific CD8 T cells in B16 melanoma tumor isolated by tetramer enrichment 18 days after tumor challenge. Right: frequency of K^b^-SIINFEKL and D^b^-gp100-specific CD8 T cells in B16-Ova tumors, without tetramer enrichment 30 days after tumor challenge. Numbers in plots indicate frequency in gate.\
(B and C) Mice were naive or immunized with VSV-gp100 (1°) and Ad-gp100 (2°) 35 days apart. Vaccinated and naive mice received B16 cells 2 days after 2°. Solid, naive; dashed, 2°.\
(B) Percentage of tumor free (left) and tumor size (right) after challenge.\
(C) Lymphocytes were isolated from tumors from naive and 2° mice in (B). D^b^-gp100-specific CD8 T cells were identified by tetramer staining without enrichment (top) or 4 h *ex vivo* peptide stimulation (bottom).\
(D) Mice were naive (black line) or immunized, as in (B) (blue line) ± anti-PD-L1 (red line). Graph shows percentage of tumor free after challenge.\
(E) Tumor size after therapeutic vaccination with indicated vectors. B16 cells were injected into naive mice or mice ≥30 days after 2° gp100 or control 2° Ova immunizations. At day 8 after B16 injection, when mice had palpable tumors, animals either received the third gp100 boost with Ad-gp100 (red line), the third boost with Ad-Ova (blue line), or remained naive (black line).\
(F) Mice were immunized with gp100 vectors, with Ova vectors, or with both concurrently. The final vaccination was given 2 days before B16-Ova challenge. Black, naive; red, gp100 only; blue, Ova only; aqua, dual-boosted. p values refer to experimental group versus naive.\
(G) Recruitment of endogenous cells to the skin 48 h after tattooing skin of dual-boosted mice with SIINFEKL or gp100 peptide on opposite flanks.\
Data based on i.v. negative staining T cells. Representative of experimental groups totaling 5--15 animals per group. \*p \< 0.05, \*\*p ≤ 0.0094, \*\*\*p ≤ 0.0008. Error bars indicate means ± SEMs.\
See also [Figures S5](#SD1){ref-type="supplementary-material"} and [S6](#SD1){ref-type="supplementary-material"}.](nihms-1542903-f0007){#F6}

###### 

KEY RESOURCE TABLE

  REAGENT or RESOURCE                                           SOURCE                                                              IDENTIFIER
  ------------------------------------------------------------- ------------------------------------------------------------------- ---------------------------------------------------
  Antibodies                                                                                                                        
  PE/Cy7 anti-CD8α antibody (53-6.7)                            BioLegend                                                           Catalog\# 100722; RRID:AB_312761
  Brilliant violet 605 anti-CD8α antibody (53-6.7)              BioLegend                                                           Catalog\# 100744; RRID:AB_2562609
  BUV737 anti-CD8a (53-6.7)                                     BD Biosciences                                                      Catalog\# 564297; RRID: AB_2722580
  FITC anti-CD8b (YTS156)                                       BioLegend                                                           Cat\# 126606; RRID: AB_961295
  AF700 anti-CD4 (RM4-5)                                        BioLegend                                                           Cat\# 100536; RRID: AB_493701
  CD4 BV711                                                     BioLegend                                                           Cat\# 100407; RRID: AB_2564586
  Alexa fluor 700 anti-CD44 antibody (IM7)                      BioLegend                                                           Catalog\# 103026; RRID: AB_493713
  Brilliant violet 785 anti-CD44 antibody (IM7)                 BioLegend                                                           Catalog\# 103059; RRID: AB_2571953
  PerCP/Cy5.5 anti-CD45.1 antibody (A20)                        Tonbo                                                               Catalog\# 65-0453-U100; RRID:AB_2621893
  PE anti-CD45.1 (A20)                                          BioLegend                                                           Cat\# 110707; RRID:AB_313496
  FITC CD45.1 (A20)                                             Tonbo                                                               Cat\# 35-0453-4500; RRID: AB_2621691
  BV711 anti-CD45.1 (A20)                                       BioLegend                                                           Cat\# 110739; RRID:AB_2562605
  FITC anti-CD45.2 (Clone 104)                                  BioLegend                                                           Cat\# 109805; RRID:AB_313442
  BV605 anti-CD45.2 (Clone 104)                                 BioLegend                                                           Cat\#10984; RRID: AB_2563485
  BV605 anti-CD69 antibody (H1.2F3)                             BioLegend                                                           Cat\# 10452; RRID: AB_11203710
  BV421 anti-CD69 antibody (H1.2F3)                             BioLegend                                                           Cat\# 104527; RRID:AB_10900250
  PE/Cy7 anti-CD69 antibody (H1.2F3)                            ebioscience-ThermoFisher                                            Catalog\# 25-0691-82; RRID:AB_469637
  PE-CF594 anti-CD69 antibody (H1.2F3)                          BD Biosciences                                                      Catalog\# 562455; RRID:AB_11154217
  efluor 450 anti-CD90.1 antibody (HIS51)                       ebioscience-ThermoFisher                                            Catalog\# 48-0900-82; RRID:AB_1272254
  PE anti-CD90.1 (OX7)                                          BD Biosciences                                                      Cat\# 554898; RRID:AB_395589
  BV510 anti-CD90.2 (30-H12)                                    BD Biosciences                                                      Cat\# 740103; RRID:AB_2739861
  Brilliant violet 510 anti-CD103 (M290)                        BD Biosciences                                                      Catalog\# 563087; RRID:AB_2721775
  FITC anti-CD103 antibody (2E7)                                Biolegend                                                           Catalog\# 121420; RRID:AB_10714791
  PE anti-CD103 (2E7)                                           Biolegend                                                           Cat\# 121406; RRID:AB_1133989
  PerCP/Cy5.5 anti-PD-1 (RMP1-30)                               Biolegend                                                           Catalog\# 109120; RRID:AB_2566641
  PE-Cy7 anti-PD1 (29F.1A12)                                    ThermoFisher                                                        Cat\# A14936; RRID:AB_2534374
  APC anti-IFNγ (XMG1.2)                                        ebioscience-ThermoFisher                                            Catalog\# 17-7311-82; RRID:AB_469504
  APC anti-IFNg (XMG1.2)                                        BD Biosciences                                                      Cat\# 554413; RRID:AB_398551
  FITC anti-IFNg (XMG1.2)                                       BD Biosciences                                                      Cat\# 554411; RRID:AB_395375)
  APC anti-TNF (MPS-XT22)                                       BD Biosciences                                                      Cat\# 554420; RRID:AB_398553
  PE-CF594 anti-Granzyme B (GB11)                               BD Biosciences                                                      Cat\# 562462; RRID:AB_2737618
  PE anti-Vb2 (B20.6)                                           Biolegend                                                           Cat\# 127908; RRID:AB_1227784)
  BV650 anti-Vb4 (KT4)                                          BD Biosciences                                                      Cat\# 743022; RRID:AB_2741219
  PE/Cy7 anti-Vb5 (MR9.4)                                       Biolegend                                                           Cat\# 139508; RRID:AB_2566021
  BV711 anti-Vb6 (RR4.7)                                        BD Biosciences                                                      Cat\# 744594; RRID:AB_2742343)
  BUV395 anti-Vb8.1/2 (MR5-2)                                   BD Biosciences                                                      Cat\# 744335; RRID:AB_2742163
  PE anti-Vb8.3                                                 BD Biosciences                                                      Cat\# 553664; RRID:AB_394980)
  PE anti-Vb9 (MRT-2)                                           Biolegend                                                           Cat\# 139804; RRID:AB_10641563
  BV785 anti-Vb10b (B21.5)                                      BD Biosciences                                                      Cat\# 742824; RRID:AB_2741076
  BV605 anti-Vb11 (RR3-15)                                      BD Biosciences                                                      Cat\# 743678; RRID:AB_2741666
  PerCPcy5.5 anti-Vb12 (MR11-1)                                 ThermoFisher                                                        Cat\# 46-5798-80; RRID:AB_10852552
  FITC anti-Vb17 (KJ23)                                         BD Biosciences                                                      Cat\# 553212; RRID:AB_394710)
  Anti-Gp100                                                    Abcam                                                               AB37078
  Anti-CD4 for *in vivo* depletion (GK1.5)                      BioXcell                                                            Cat\# BE0003-1; RRID:AB_1107636
  Anti-CD8 for *in vivo* depletion (YTS169)                     BioXcell                                                            Cat\# BE0117; RRID:AB_10950145
  Anti-PD-L1 for *in vivo* blockade (10F9.G2)                   BioXcell                                                            Cat\# BE0101; RRID:AB_10949073)
  Bacterial and Viral Strains                                                                                                       
  Lymphocytic choriomeningitis virus (LCMV)- Armstrong strain   Dr. R. Ahmed, Emory University                                      N/A
  Vesicular stomatitis virus (VSV)-Ova                          Dr. Leo Lefrancois, UCONN                                           N/A
  Listeria Monocytogenes (LM)-Ova                               Dr. Leo Lefrancois, UCONN                                           N/A
  Vaccinia virus (VV)- Ova                                      Dr. Leo Lefrancois, UCONN                                           N/A
  Adenovirus (Ad) 5-Ova                                         Dr. Thomas Griffith, U of Minnesota                                 N/A
  Vesicular stomatitis virus (VSV)-hgp100                       Dr. Kimberly Schluns, MD Anderson                                   N/A
  Vaccinia virus (VV)-gp100                                     Dr. Zong Sheng Guo, U of Pittsburgh                                 N/A
  Adenovirus (Ad)- serotype 2 gp100                             Dr. Nicholas Restifo, NIH                                           N/A
  Adenovirus (Ad)- serotype 5 gp100                             Iowa Viral Vector Core                                              N/A
  MCMV-Ova                                                      Dr. Ann Hill, OHSU                                                  N/A
  Cell Lines                                                                                                                        
  B16 cell line                                                 NCI-DTP                                                             Cat\# B16F10; RRID:CVCL_0159
  B16-Ova                                                       NCI-DTP                                                             RRID:CVCL_WM77
  Chemicals, Peptides, and Recombinant Proteins                                                                                     
  SIINFEKL                                                      New England Peptide                                                 N/A
  EGSRNQDWL                                                     New England Peptide                                                 N/A
  KVPRNQDWL                                                     New England Peptide                                                 N/A
  DL-Dithioerythritol (DTE)                                     VWR Scientific                                                      Catalog\# 97061-642
  Collagenase I                                                 Worthington Biochemicals                                            Catalog\# LS004197
  Collagenase III                                               Worthington Biochemicals                                            Catalog\# LS004183
  CFSE                                                          BD Biosciences                                                      Cat\# 565082
  4',6-Diamidino-2-Phenylindole dihydrochloride (DAPI)          Sigma Aldrich                                                       Catalog\# D9542
  Live dead Ghost Dye Red 780                                   Tonbo Biosciences                                                   Catalog\# 13-0865-T500
  H-2Db/GP~33-41~ KAVYNFATM biotinylated monomer                Prepared in house following NIAID tetramer core facility protocol   N/A
  H-2Kb /OVA~257-264~ SIINFEKL biotinylated monomer             Prepared in house following NIAID tetramer core facility protocol   N/A
  H-2Kb/B8R RGYVYQGL biotinylated monomer                       Prepared in house following NIAID tetramer core facility protocol   N/A
  H-2Kb/N TSYKFESV biotinylated monomer                         Prepared in house following NIAID tetramer core facility protocol   N/A
  H-2Db/M45 HGIRNASFI biotinylated monomer                      Prepared in house following NIAID tetramer core facility protocol   N/A
  H-2Kb/IE3 RALEYKNL biotinylated monomer                       Prepared in house following NIAID tetramer core facility protocol   N/A
  I-A^b^/LM LLO~190-201~ tetramer                               Dr. Marc Jenkins, U of Minnesota                                    N/A
  H2-Db/ mgp100 EGSRNQDWL biotinylated monomer                  Prepared in house following NIAID tetramer core facility protocol   N/A
  H2-Db/ hgp100 KVPRNQDW biotinylated monomer                   Prepared in house following NIAID tetramer core facility protocol   N/A
  Streptavidin-APC (monomer tetramerization)                    Life Technologies                                                   Catalog\# S868
  Streptavidin-PE (monomer tetramerization)                     Life Technologies                                                   Catalog\# S866
  Critical Commercial Assays                                                                                                        
  iFABP- ELISA                                                  Elabscience                                                         E-EL-M0735
  Experimental Models: Organisms/Strains                                                                                            
  C57BL/6J                                                      The Jackson Laboratory                                              Catalog\# JAX:000664; RRID: IMSR_JAX:000664
  iFABP-OVA CD45.2 or CD45.1                                    Dr. Leo Lefrancois, UCONN                                           N/A
  P14                                                           Dr. R. Ahmed, Emory University                                      Catalog\# MUGEN:M189001; RRID: IMSR_MUGEN:M189001
  OT-I 45.1                                                     Dr. K. Hogquist, Univ. of Minnesota                                 Catalog\# JAX:003831; RRID: IMSR_JAX:003831
  OT-I Thy1.1                                                   Dr. K. Hogquist, Univ. of Minnesota                                 N/A
  B6 CD45.1                                                     Bred in house                                                       N/A
  B6 Thy1.1                                                     The Jackson Laboratory                                              Catalog\# JAX:000406; RRID: IMSR_JAX:000406
  Software and Algorithms                                                                                                           
  Flowjo v9 and v10                                             Treestar Inc                                                        RRID:SCR_008520
  Prism 7                                                       Graphpad Inc                                                        RRID:SCR_002798
  Image J4                                                      NIH                                                                 N/A

###### Highlights

-   Iterative stimulation with antigen and inflammation reverses CD8^+^ T cell tolerance

-   Tolerance reversal results in avidity maturation and enhanced antigen sensing

-   Expanded self-specific CD8^+^ T cells form T~RM~ in lymphoid and non-lymphoid tissues

-   Self-specific CD8^+^ T cells control tumor growth without concomitant autoimmunity
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